GSK Kick Starts Late-Stage Study With Medicago-Partnered COVID-19 Vaccine

Loading...
Loading...

GlaxoSmithKline Plc GSK hopes for better luck with its second partner Medicago, after tripping up in a recent COVID-19 vaccine test with Sanofi SA SNY

  • GSK and Medicago will start Phase 3 testing of Medicago’s COVID-19 vaccine candidate combined with GSK’s pandemic adjuvant.
  • The companies penned a vaccine deal last year to test Medicago’s plant-derived recombinant coronavirus-like particles (CoVLPs) with GSK’s pandemic adjuvant system that has been used in previous epidemics.
  • A similar vaccine approach didn’t initially work out very well for Sanofi and GlaxoSmithKline, which posted weak results in older patients.
  • Last month, the companies corrected the vaccine’s formulation, GSK and Sanofi began a Phase 2 clinical trial of a new version of the vaccine.
  • Phase 3 with Medicago will be conducted in about 30,000 patients while also assessing the shot “to address emerging variants” in a feasibility test.
  • As part of the program, patients in the trial will get two doses of 3.75 micrograms of CoVLPs administered 21 days apart.
  • The trial is part of the ongoing phase 2/3 study that started last November.
  • The Phase 2 part of the trial should see early data out next month.
  • GSK, along with Vir Biotechnology Inc’s VIR, is evaluating a COVID-19 antibody therapy. Interim analysis of data from 583 patients demonstrated an 85% reduction in hospitalization or death.
  • Last week, Sanofi and Translate Bio began a trial of the mRNA Covid-19 vaccine.
  • Price Action: SNY and GSK shares are trading 0.8% and 0.78% higher at $49.11 and $36.16, respectively, in the market trading hours on the last check Tuesday.
Loading...
Loading...
Posted In: BiotechNewsHealth CareContractsFDAGeneralCOVID-19 VaccinePhase 3 Study
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...